Mankind Pharma engages in developing, manufacturing, and marketing a variety of pharmaceutical formulations for chronic and acute therapeutic usage. It was the fourth largest in terms of domestic sales and the 3rd largest in terms of sales volume for Moving Annual Total (MAT) in FY22.
The company is the youngest among the five largest Indian pharmaceutical companies with a focus on the domestic market. In Fiscal 2022, the company generated 97.60% of the total revenue from operations from domestic sales, which is the highest among peers.
The company sells 36 brands under its umbrella, each of which has achieved over Rs. 500 million in domestic sales in FY22.
The company sales have grown at 16% CAGR from 2020 to 2022.
Outside the Indian market, the corporation has a presence in the United States, Sri Lanka, Bangladesh, and Nepal.
Mankind Pharma Ltd IPO Details
Mankind Pharma Ltd IPO dates are announced and the bidding window will open on April 25, 2023. It is an offer for sale issue of 40,058,844 shares with a face value of Rs. 1 per share.
The price band for the offer is fixed at Rs. 1,026 - 1,080 per share. Retail investors can bid for a minimum of one lot of 13 shares.
Mankind Pharma Ltd IPO Objective
- Mankind Pharma Ltd IPO is a 100% Offer for sale issue and all the proceeds will be received by the selling shareholders.
Should you invest in Mankind Pharma Ltd?
You might want to look at the top reasons below before investing.
- It has one of the largest networks of medical representatives in PAN India. According to the IQVIA Medical Audit report of March 2022, 80% of doctors in India have been prescribed medicines by Mankind Pharma.
- In the last five years, Mankind Pharma has generated the highest share of prescriptions in the Indian Pharmaceutical Market.
- The company has consistently outperformed its peers in the Indian Pharmaceutical Market sphere.
- In the domestic sales segment, the company’s rank improved from 8th in 2012 to 4th in 2022.
Between FY 2020 and the period ending in December 31, 2022, company’s market share in terms of Domestic Sales in the IPM has increased from 4.1 to 4.3%, fastest among the 10 largest corporations in the same field.
Mankind Pharma Ltd Noteworthy highlights
- Between FY2020 and FY2022, the company’s revenue from operations increased from Rs. 60,647 million to Rs. 82,298 million, 1.5x of the IPM.
- In that period the company’s total revenue from operations growth was 16% against the industry average of 11% compounded annual growth.
Mankind Pharma Company Financials
| Particulars | March 31, 2022 (Rs.in million) | March 31, 2021 (Rs.in million) |
|---|---|---|
| Revenue from Operations | 77,815.55 | 62,144.31 |
| Net Profit | 14,529.56 | 12,930.34 |
| PAT Margin | 18.67% | 20.81% |
| EBITDA | 2,003.80 | 1,659.78 |
| EBITDA Margin | 25.75% | 26.71% |
| EPS (Basic) | 35.78 | 31.59 |
| ROE | 25.99% | 30.30% |
Know before investing
Strengths
3It recorded the fastest growth in domestic sales among the 10 largest pharmaceuticals during FY20-22.
The company has a presence in several segments of acute, chronic therapeutic, and consumer healthcare products.
Eighteen of their brands had domestic sales of over 1 billion in FY22.
Risks
3The corporation operates in a highly regulated industry and requires extensive licensing for manufacturing and marketing.
It requires obtaining and renewing statutory and regulatory approvals and licences to continue operations.
Disruption in manufacturing and R&D can have an adverse impact on the company’s operational and financial performance.
